Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Takeda Pharmaceutical director John Maraganore reported equity compensation and related tax settlements. He received 3,800 Ordinary Shares as a grant and 1,319 Tax Obligation Awards, each tied to one Ordinary Share that will vest and convert on June 1, 2029. A prior block of 1,152 Tax Obligation Awards, economically equivalent to 1,152 Ordinary Shares, was disposed to the issuer at a weighted average price of JPY 4,931.2 per share, primarily to cover tax obligations. Following these events, he directly holds 10,400 Ordinary Shares and 13,800 American Depositary Shares.
Takeda Pharmaceutical director Kimberly A. Reed reported new equity awards and related tax transactions. She received a grant of 3,800 Ordinary Shares as restricted stock units that vest on June 1, 2029, plus 1,319 Tax Obligation Awards economically equivalent to Ordinary Shares vesting on the same date.
Separately, 1,152 Tax Obligation Awards tied to Ordinary Shares were disposed of at a weighted average price of JPY 4,931.2 per share, primarily to cover tax obligations, with any remaining cash proceeds to be delivered to her on July 10. After these updates, she directly holds 10,400 Ordinary Shares and 15,175 American Depositary Shares.
Takeda Pharmaceutical director Masami Iijima reported compensation-related equity activity. On July 1, he received a grant of 1,800 Ordinary Shares as a restricted stock unit award, increasing his direct holdings to 14,601 shares. The RSUs vest on June 1, 2029.
He also received 1,937 Tax Obligation Awards, each economically equivalent to one Ordinary Share and payable in cash at vesting primarily to cover tax obligations at the then-current market price. Separately, 2,152 Tax Obligation Awards tied to previously vested shares were disposed to the issuer on July 10 at a weighted average price of JPY 4,931.2 per share, with any remaining sale proceeds to be delivered to him.
Takeda Pharmaceutical Co. Ltd. director Bruce D. Broussard received equity-based compensation rather than buying shares on the market. He was granted 3,800 American Depositary Shares (ADS) on a cost-free basis, increasing his direct holdings to 4,595 ADS after the award.
The grant represents restricted stock units (RSUs), each linked to one Ordinary Share that will convert into an equivalent number of ADS when the award vests on June 1, 2029. These RSUs are contingent and only settle if vesting conditions are met.
Broussard was also granted 1,319 units of a Tax Obligation Award, economically equivalent to one Ordinary Share each. Upon vesting on June 1, 2029, these are designed to pay cash at the then-current market price primarily to cover related tax obligations, rather than delivering additional shares.
Takeda Pharmaceutical director Paulus Stoffels reported an equity compensation grant. He acquired 3,800 Ordinary Shares on a grant or award basis, bringing his directly held Ordinary Shares to 3,800.
He was also granted 1,307 Tax Obligation Awards, each economically equivalent to one Ordinary Share. The related restricted stock units vest on June 1, 2029 and will convert into Ordinary Shares, which are then deliverable as American Depositary Shares. The Tax Obligation Awards are structured to pay cash at vest, primarily to cover tax obligations based on the then-current market price.
Takeda Pharmaceutical director Kimura Koichiro received new equity-based compensation tied to Ordinary Shares. He was granted 1,800 Ordinary Shares on an award basis at a price of $0.00 per share, bringing his directly held Ordinary Shares to 1,800.
He also received 1,937 units of a Tax Obligation Award, each economically equivalent to one Ordinary Share. According to the disclosure, the 1,800-share award represents restricted stock units that vest on June 1, 2029, while the 1,937-unit Tax Obligation Award will convert to a cash payment at vest primarily to cover tax obligations at the then-current market price.
Takeda Pharmaceutical director Miki Tsusaka reported routine equity compensation and tax-related transactions. She received a grant of 1,800 Ordinary Shares, bringing her direct holdings to 8,200 shares. She was also granted 1,937 Tax Obligation Awards, each economically equivalent to one Ordinary Share and scheduled to vest on June 1, 2029.
In a separate move, 2,152 Tax Obligation Awards were disposed of to the issuer after vesting, converting into a cash payment primarily to cover tax obligations. The associated Ordinary Shares were sold at a weighted average price of JPY 4,931.2, within a range from JPY 4,883 to JPY 5,045, with any remaining proceeds delivered to her on July 10.
Takeda Pharmaceutical's President, Japan Pharma Business Unit, Asuka Miyabashira reported routine equity compensation and related tax-settlement activity. Miyabashira acquired 1,500 Ordinary Shares as a share grant, bringing direct ownership to 4,500 shares after the transaction. On the same date, Miyabashira also received several Tax Obligation Awards, each economically equivalent to one Ordinary Share, which will convert to cash at future vesting dates primarily to cover tax obligations. Separately, 1,022 Tax Obligation Awards that had vested were disposed of to the issuer at a weighted average price of JPY 4,931.4 per share, with most proceeds used for taxes and any remaining cash to be delivered to Miyabashira on July 10. Following these grants, 1,392 Tax Obligation Awards remain outstanding.
Takeda Pharmaceutical director and Chief Financial Officer Furuta Milano reported a mix of equity compensation awards and tax-related dispositions. On July 1, 2026, Milano received 12,300 Ordinary Shares as a grant, bringing direct holdings to 70,200 shares. The filing notes these restricted stock units vest in three equal annual installments beginning on June 1, 2027. Milano also received several Tax Obligation Awards, each economically equivalent to one Ordinary Share and scheduled to convert into cash at future vesting dates primarily to cover tax obligations. On July 10, 2026, 16,619 Tax Obligation Awards tied to the same number of underlying Ordinary Shares were disposed of to the issuer, with the Ordinary Shares sold at a weighted average price of JPY 4,931.5 per share to satisfy tax obligations, and any remaining proceeds to be delivered to Milano.
Platford Giles Richard reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical reported that President, IBU, Giles Richard Platford received an equity award in the form of 49,558 American Depositary Shares. The award was granted at no cash cost to him as a compensation-related grant.
The award is structured as restricted stock units, with each RSU representing a contingent right to receive one American Depositary Share. The RSUs vest in three equal annual installments beginning on July 1, 2027. After this grant, Platford directly holds 346,921 American Depositary Shares.